Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Gurgaon, India-based Ranbaxy Laboratories has delayed plans to spin off its research unit until the second half of the year, but noted during a Jan. 17 press conference that it had settled a key lawsuit over Flomax (tamsulosin) and expanded a development deal with GlaxoSmithKline that will secure earnings momentum

You may also be interested in...



Astellas/Boehringer Get Flomax Market Exclusivity Extension Through Pediatric Study

Tokyo-based Astellas Pharma announced that U.S. marketing partner Boehringer Ingelheim has obtained six-month pediatric exclusivity for blockbuster benign prostate hyperplasia drug Flomax (tamsulosin). The Flomax substance patent expires in October, and the period of market exclusivity will now be extended to April 2010

Astellas/Boehringer Get Flomax Market Exclusivity Extension Through Pediatric Study

Tokyo-based Astellas Pharma announced that U.S. marketing partner Boehringer Ingelheim has obtained six-month pediatric exclusivity for blockbuster benign prostate hyperplasia drug Flomax (tamsulosin). The Flomax substance patent expires in October, and the period of market exclusivity will now be extended to April 2010

Ranbaxy To Announce New Drug Development Tie-Up In May

NEW DELHI - India's top generic drug firm Ranbaxy Laboratories expects to announce a new tie up with a large multinational drug firm in May to develop new chemical entities at its recently spun-off Life Science Research unit similar to a current deal with GlaxoSmithKline inked in 2003 and expanded last year, the company's chief executive said

Related Content

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel